Archon Biosciences, Inc.

Archon Biosciences is a biotechnology company developing geometrically tunable protein therapeutics with unique distribution, engagement, and function to target pathways other technologies cannot. Their innovative biologic class, the Antibody Cage (AbC), leverages structural design and AI to create molecules with new structures and functions, aiming to unlock challenging therapeutic targets. Recognized by the 2024 Nobel Prize in Chemistry, their platform combines computational protein design with structural control to advance biologics. The company is led by a management team including CEO and Co-Founder James Lazarovits, CTO and Co-Founder George Ueda, and others, with a board of directors and investors supporting their mission.